EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Hybridization of Clinically Relevant P2X7 Antagonists

Nicholas B Lynch, Charleigh T A Agius, André D J McKenzie, Jessica O'Driscoll, Angus Tolmie, Taylor R Garrett, Eryn Werry iD, Michael Kassiou iD

ChemMedChem · 14.07.2026 · 21 (13)

DOI: 10.1002/cmdc.70371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 08.07.2026. Verfasst von Nicholas B Lynch und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Receptors, Purinergic P2X7, Purinergic P2X Receptor Antagonists. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government Research Training Program..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The P2X7 receptor plays a pivotal role in the development of neurodegenerative disease states, yet no therapies targeting this receptor have reached the market to date. This work utilized a hybridization approach to combine clinically relevant antagonists AZD‐9056 and JNJ‐54175446 to discover new P2X7 antagonists. Here, we report the synthesis and in vitro and in silico evaluation of a library of 22 compounds to explore new chemical space around these clinically validated molecules. This study emphasizes the value of molecular hybridization in drug discovery and provides the basis for future P2X7 receptor antagonist development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Purinergic P2X7Purinergic P2X Receptor AntagonistsHumansStructure-Activity RelationshipMolecular Structure

Stichwörter der Autor:innen

P2X receptorP2X7P2X7R antagonistcentral nervous systemneurodegenerative disease

Substanzen

Receptors, Purinergic P2X7Purinergic P2X Receptor Antagonists

Autor:innen und Institutionen

  • School of Chemistry, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia.
  • Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Eryn Werry, Michael Kassiou

Förderung

  • Australian Government Research Training Program.

Zitieren

APA

Lynch, N. B., Agius, C. T. A., McKenzie, A. D. J., O'Driscoll, J., Tolmie, A., Garrett, T. R., Werry, E., & Kassiou, M. (2026). Molecular Hybridization of Clinically Relevant P2X7 Antagonists. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70371

Vancouver

Lynch NB, Agius CTA, McKenzie ADJ, O'Driscoll J, Tolmie A, Garrett TR, et al. Molecular Hybridization of Clinically Relevant P2X7 Antagonists. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70371

BibTeX
@article{Lynch2026,
  author = {Lynch, Nicholas B and Agius, Charleigh T A and McKenzie, André D J and O'Driscoll, Jessica and Tolmie, Angus and Garrett, Taylor R and Werry, Eryn and Kassiou, Michael},
  title = {Molecular Hybridization of Clinically Relevant P2X7 Antagonists},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70371}
}
Kostenlos starten →